FDA approved Par Health's generic drug, which is the generic version of Merck's Janumet® XR.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved Par Health's generic drug, which is the generic version of Merck's Janumet® XR.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Par Health launched a generic drug in the US.Sub-event
Generic approval granted for Par Health's generic version of Merck's Janumet® XR.1 source
Keep exploring
The entities involved
- FDA
-
Merck Sharp & Dohme
company in Madrid, Spain
Nothing else this week.
Related events
- Merck has set the list price for a drug that received approval from the FDA.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- A product was launched in the U.S. market following FDA involvement.
- FDA approves generic drug market entry, with Lanreotide challenging Somatuline Depot market share.
- Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.